2μg(R: reducing conditions)
Product Details
Product Details
Product Specification
Species | Human |
Accession | Q9P206 |
Amino Acid Sequence | Protein sequence (Q9P206, Thr113-Asp201, with C-10*His) TSYVAESSTAEDALSIRSEMIQRKGSTFRPHDSFPKSGKSGRRRRERRSTVLGLPQHVQKELGLRNEREAPGTPRAPGARDAVRIPTVDGGGGSHHHHHHHHHH |
Expression System | HEK293 |
Molecular Weight | Predicted MW: 11.6 kDa Observed MW: 10, 11, 18-25 kDa |
Purity | >95% by SDS-PAGE |
Tag | with C-10*His |
Physical Appearance | Lyophilized Powder |
Storage Buffer | Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4. |
Reconstitution | Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation. |
Stability & Storage | 12 months from date of receipt, -20 to -70 °C as supplied. 6 months, -20 to -70 °C under sterile conditions after reconstitution. 1 week, 2 to 8 °C under sterile conditions after reconstitution. Please avoid repeated freeze-thaw cycles. |
Background
KIAA1522 was identified in 2000 by sequencing of human tissues. The KIAA1522 gene is localized on human chromosome 1p35.1 and contains 9 exons. In previous reports, KIAA1522 is demonstrated to be highly expressed in esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and breast cancer cell lines, and was related to tumor differentiation, invasion and metastasis. KIAA1522 expression was overexpressed in colorectal cancer and was positively correlated with poor prognosis of patients. However, its biological role and molecular mechanism in mediating tumor progression and distant metastasis have not yet been investigated.
Picture
Picture
SDS-PAGE
